Supernus Pharmaceuticals Share Price Today
(NASDAQ: SUPN)

Name: Supernus Pharmaceuticals Share Price Today (NASDAQ: SUPN) - Supernus Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Supernus Pharmaceuticals share price is $32.16 & ₹2,791.52 as on 18 Mar 2025, 2.30 'hrs' IST

$32.16

▲

0.9

(2.88%)

Market is closed - opens 7 PM, 18 Mar 2025

View live Supernus Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Supernus Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Supernus Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Supernus Pharmaceuticals share price movements

Today's Low: $30.94
Today's High: $32.35
$32.16
3.79%
Downside
Day's Volatility :4.36%
Upside
0.59%
52 Weeks Low: $25.53
52 Weeks High: $40.28
$32.16
20.62%
Downside
52 Weeks Volatility :36.62%
Upside
20.16%

Supernus Pharmaceuticals (SUPN) Returns

Period	Supernus Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-13.69%	4.1%	0.0%
6 Months	-1.45%	-6.9%	0.0%
1 Year	-8.57%	-0.3%	0.0%
3 Years	0.29%	6.4%	-14.3%

Supernus Pharmaceuticals (SUPN) Key Statistics

in dollars & INR

Previous Close	$31.26
Open	$31.15
Today's High	$32.35
Today's Low	$30.94
Market Capitalization	$1.7B
Today's Volume	$460.7K
52 Week High	$40.28
52 Week Low	$25.53
Revenue TTM	$661.8M
EBITDA	$141.8M
Earnings Per Share (EPS)	$1.32
PE Ratio	23.68
Profit Margin	11.16%
Quarterly Earnings Growth YOY	14.45%
Return On Equity TTM	7.55%

How to invest in Supernus Pharmaceuticals Stock (SUPN) from India?

It is very easy for Indian residents to invest directly in Supernus Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Supernus Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Supernus Pharmaceuticals or SUPN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Supernus Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Supernus Pharmaceuticals shares which would translate to 0.027 fractional shares of Supernus Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Supernus Pharmaceuticals, in just a few clicks!

Returns in Supernus Pharmaceuticals (SUPN) for Indian investors in Rupees

The Supernus Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Supernus Pharmaceuticals investment value today

Current value as on today

₹98,839

Returns

₹1,161

(-1.16%)

Returns from Supernus Pharmaceuticals Stock

₹5,937 (-5.94%)

Dollar Returns

₹4,776 (+4.78%)

Indian investors sentiment towards Supernus Pharmaceuticals (SUPN)

-41%

Period: Feb 15, 2025 to Mar 17, 2025. Change in 30 Days versus previous period

Search interest for Supernus Pharmaceuticals Stock from India on INDmoney has decreased by -41% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Supernus Pharmaceuticals

BlackRock Inc
17.91%
Vanguard Group Inc
11.02%
Armistice Capital, LLC
8.66%
Dimensional Fund Advisors, Inc.
5.16%
Macquarie Group Ltd
4.71%
State Street Corp
3.92%

Analyst Recommendation on Supernus Pharmaceuticals

Buy

80%Buy

20%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Supernus Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Supernus Pharmaceuticals Stock (SUPN)

What analysts predicted

Upside of 20.65%

Target:

$38.80

Current:

$32.16

Insights on Supernus Pharmaceuticals Stock (Ticker Symbol: SUPN)

Price Movement
In the last 7 days, SUPN stock has moved down by -4.8%
Decreasing Revenue
Revenue is down for the last 2 quarters, 175.68M → 174.15M (in $), with an average decrease of 0.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 38.49M → 15.32M (in $), with an average decrease of 60.2% per quarter
SUPN vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 102.6% return, outperforming this stock by 107.8%
SUPN vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 117.4% return, outperforming this stock by 117.5%
Price to Sales
ForSUPN every $1 of sales, investors are willing to pay $2.7, whereas for Intra-cellular Therapies, Inc., the investors are paying $19.9 for every $1 of sales.

Supernus Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Supernus Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Supernus Pharmaceuticals (SUPN) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Supernus Pharmaceuticals Inc	-21.36%	-1.45%	-8.57%	0.29%	87.86%
Intra-cellular Therapies, Inc.	2.58%	74.76%	100.8%	123.92%	919.89%
Haleon Plc Spon Ads	1.6%	-4.69%	25.0%	36.98%	36.98%
Zoetis Inc.	3.05%	-17.6%	-5.52%	-17.18%	57.59%
Neurocrine Biosciences Inc.	-2.83%	-9.45%	-20.58%	17.62%	40.19%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Supernus Pharmaceuticals Inc	23.68	23.68	1.47	1.96	0.08	0.03	NA	18.58
Intra-cellular Therapies, Inc.	NA	NA	0.0	0.13	-0.09	-0.07	NA	10.81
Haleon Plc Spon Ads	24.76	24.76	1.78	0.37	0.09	0.04	0.02	1.8
Zoetis Inc.	29.48	29.48	2.85	6.07	0.51	0.15	0.01	10.64
Neurocrine Biosciences Inc.	33.66	33.66	0.27	6.36	0.14	0.1	NA	26.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Supernus Pharmaceuticals Inc	Buy	$1.7B	87.86%	23.68	11.16%
Intra-cellular Therapies, Inc.	Buy	$14.0B	919.89%	NA	-10.97%
Haleon Plc Spon Ads	Buy	$45.9B	36.98%	24.76	12.84%
Zoetis Inc.	Buy	$72.2B	57.59%	29.48	26.86%
Neurocrine Biosciences Inc.	Buy	$11.0B	40.19%	33.66	14.49%

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Organization	Supernus Pharmaceuticals
Employees	674
CEO	Mr. Jack A. Khattar M.B.A.
Industry	Health Technology

Management People of Supernus Pharmaceuticals

Name	Title
Mr. Jack A. Khattar M.B.A.	Founder, President, CEO, Secretary & Director
Mr. Timothy C. Dec	Senior VP & CFO
Dr. Padmanabh P. Bhatt Ph.D.	Chief Scientific Officer & Senior VP of Intellectual Property
Mr. Frank Mottola	Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs
Dr. Jonathan Rubin M.B.A., M.D.	Senior VP of Research & Development and Chief Medical Officer
Mr. Kevin T. Anderson Esq.	Compliance Officer
Dr. Todd Horich M.B.A., Ph.D.	Senior Vice President of Marketing, Commercial Operations & Market Access
Mr. Taylor Raiford	Senior Vice President of Sales
Dr. Bryan A. Roecklein Ph.D.	Senior Vice President of Corporate Development
Mr. Jeff Bozick	Senior Vice President of Supply Chain

Important FAQs about investing in SUPN Stock from India :

What is Supernus Pharmaceuticals share price today?

Supernus Pharmaceuticals share price today stands at $32.16, Open: $31.15 ; Previous Close: $31.26 ; High: $32.35 ; Low: $30.94 ; 52 Week High: $40.28 ; 52 Week Low: $25.53.

The stock opens at $31.15, after a previous close of $31.26. The stock reached a daily high of $32.35 and a low of $30.94, with a 52-week high of $40.28 and a 52-week low of $25.53.

Can Indians buy Supernus Pharmaceuticals shares?

Yes, Indians can invest in the Supernus Pharmaceuticals (SUPN) from India.

With INDmoney, you can buy Supernus Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Supernus Pharmaceuticals at zero transaction cost.

How can I buy Supernus Pharmaceuticals shares from India?

It is very easy to buy Supernus Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Supernus Pharmaceuticals (SUPN) be purchased?

Yes, you can buy fractional shares of Supernus Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Supernus Pharmaceuticals stocks?

To start investing in Supernus Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.